75 inter-disciplinary, multi-institutional grants would be supported for high-risk, ambitious research ideas, milestones-driven collaborative research in all domain areas of the biotech sector
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Naproxen Sodium Capsules, 220 mg, of Bionpharma
Collaboration supports multiple discovery efforts, including vaccines
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Company appoints five new independent directors to reconstituted board
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
Subscribe To Our Newsletter & Stay Updated
